Nasdaq btai.

NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Shares of BioXcel Therapeutics ( BTAI 2.61%) had crashed 22.5% as of 11:56 a.m. EST on Monday. The steep decline came after Goldman Sachs ( GS 0.15%) analyst Corinne Jenkins downgraded BioXcel ...BioXcel Therapeutics (NASDAQ:BTAI) announces that the FDA has accepted for filing the New Drug Application (NDA) for BXCL501, an investigational, orally dissolving thin film formulation of ...

25 May 2023 ... Healthcare Stocks on the Move Thursday: ELEV, CDIO, HSCS, XBIT, ANNX, BIOC, BTAI, BHG · These Healthcare stocks are trading higher: · These ...

According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...

BioXcel just announced a big change. Keith Noonan BioXcel Therapeutics (NASDAQ:BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...Find the latest Earnings Report Date for TG Therapeutics, Inc. Common Stock (TGTX) at Nasdaq.com.

NEW HAVEN, Conn., May 25, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...

The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for ...NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ...BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ...21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

Aug 14, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million. 0. On November 15, 2023, BioXcel Therapeutics (NASDAQ:BTAI) shared its Q3 earnings results. Let’s take a closer look at the key takeaways from the announcement: – Earnings: BioXcel Therapeutics fell short of estimated earnings by 20.61%, reporting an EPS of $-1.58 compared to the estimated $-1.31. This represents a significant deviation ...BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...Oct 10, 2023 · Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ... NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or [email protected]. Please see full Prescribing Information . BioXcel Therapeutics, Inc., is a biopharmaceutical ...

BTAI - Stock Quotes for BTAI Ent Holdg, NASDAQ: BTAI Stock Options Chain, Prices and News - Webull MARKET BTAI BTAI Bioxcel Therapeutics Inc NASDAQ 3.772 -0.028 …Aug 16, 2022 · The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ... Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NEW HAVEN, Conn., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ...BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and ...

BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ...

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics (NASDAQ:BTAI) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial.. According to a ...On November 14, 2023, BioXcel Therapeutics Inc ( NASDAQ:BTAI) released its 8-K filing, announcing strategic advancements and financial results for the third quarter ended September 30, 2023. The ...Discover historical prices for BTAI stock on Yahoo Finance. View daily, weekly or monthly format back to when BioXcel Therapeutics, Inc. stock was issued. ... Nasdaq Futures 15,961.50-47.25 (-0.30 ...NEW HAVEN, Conn., Aug. 20, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information. Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price.BTAI U.S.: Nasdaq BioXcel Therapeutics Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 30, 2023 11:20 a.m. EST Real time quote $ 3.8800 -0.0200 -0.51% Previous Close...Fintel reports that on June 30, 2023, Mizuho reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation.. Analyst Price Forecast Suggests 205.94% Upside. As of June 2 ...BioXcel Therapeutics will host a conference call and webcast May 9, 2022, at 8:30 a.m., ET, to discuss its first quarter 2022 financial results and provide an update on recent operational ...27 Oct 2023 ... Fintel reports that on October 26, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...NASDAQ: BTAI ® BXCL701 Key Opinion Leader Day February 21, 2023 ... | April 10, 2023

The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Instagram:https://instagram. fwrd stocklgbt friendly health insuranceus30 futuresstock biggest gainers Dec 3, 2023 · 2017. 183. Vimal Mehta. https://www.bioxceltherapeutics.com. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or ... NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... how much does health insurance cost per month in arizonahow to invest in pre ipo companies The 5 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 11.00, with a high estimate of 18.00 and a low estimate of 4.00. The median estimate ... stock price alb NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...Price. %Change. 3.830. -1.79%. paper trading platform. Webull offers BTAI Ent Holdg (BTAI) historical stock prices, in-depth market analysis, NASDAQ: BTAI real-time stock quote data, in-depth charts, free BTAI options chain data, and a fully built financial calendar to help you invest smart. Buy BTAI stock at Webull.